| scholarly article | Q13442814 |
| review article | Q7318358 |
| P50 | author | Robert S. Negrin | Q110528996 |
| P2093 | author name string | Robert Zeiser | |
| P2860 | cites work | FOXP3 controls regulatory T cell function through cooperation with NFAT | Q24298179 |
| Development and function of T cells in mice rendered interleukin-2 deficient by gene targeting | Q24318910 | ||
| Immunopharmacology of rapamycin | Q28285198 | ||
| Interleukin-2 receptor α chain regulates the size and content of the peripheral lymphoid compartment | Q28587823 | ||
| Uncoupling p70(s6) kinase activation and proliferation: rapamycin-resistant proliferation of human CD8(+) T lymphocytes | Q32024520 | ||
| Distinct IL-2 receptor signaling pattern in CD4+CD25+ regulatory T cells | Q33742099 | ||
| Human CD4(+)CD25(+) thymocytes and peripheral T cells have immune suppressive activity in vitro | Q33942128 | ||
| Interleukin 2 signaling involves the phosphorylation of Stat proteins | Q34007160 | ||
| Fluticasone propionate increases CD4CD25 T regulatory cell suppression of allergen-stimulated CD4CD25 T cells by an IL-10-dependent mechanism | Q34341871 | ||
| Regulatory T cells induced by 1 alpha,25-dihydroxyvitamin D3 and mycophenolate mofetil treatment mediate transplantation tolerance. | Q34516841 | ||
| Interleukin 2 signaling is required for CD4(+) regulatory T cell function | Q34527240 | ||
| CD28 costimulation of developing thymocytes induces Foxp3 expression and regulatory T cell differentiation independently of interleukin 2. | Q34554035 | ||
| IL-2 administration increases CD4+ CD25(hi) Foxp3+ regulatory T cells in cancer patients | Q34657691 | ||
| CD4+ CD25+ suppressor T cells: more questions than answers | Q34716304 | ||
| PTEN inhibits IL-2 receptor-mediated expansion of CD4+ CD25+ Tregs | Q34997285 | ||
| IL-2, regulatory T cells, and tolerance | Q35700529 | ||
| Nonredundant roles for Stat5a/b in directly regulating Foxp3 | Q35828667 | ||
| TNF downmodulates the function of human CD4+CD25hi T-regulatory cells | Q35849817 | ||
| Tolerance, not immunity, crucially depends on IL-2. | Q35877199 | ||
| Requirement for an initial signal from the membrane-proximal region of the interleukin 2 receptor gamma(c) chain for Janus kinase activation leading to T cell proliferation | Q36026082 | ||
| Determinants of sensitivity and resistance to rapamycin-chemotherapy drug combinations in vivo | Q36100451 | ||
| Differential impact of mammalian target of rapamycin inhibition on CD4+CD25+Foxp3+ regulatory T cells compared with conventional CD4+ T cells | Q36384673 | ||
| Insights into the mechanism of FTY720 and compatibility with regulatory T cells for the inhibition of graft-versus-host disease (GVHD). | Q36384836 | ||
| Contrasting effects of cyclosporine and rapamycin in de novo generation of alloantigen-specific regulatory T cells | Q37317866 | ||
| CD4+CD25+ regulatory T-cell lines from human cord blood have functional and molecular properties of T-cell anergy | Q40397533 | ||
| Inhibition of CD4+CD25+ regulatory T-cell function by calcineurin-dependent interleukin-2 production | Q41908710 | ||
| IL-2 regulates FOXP3 expression in human CD4+CD25+ regulatory T cells through a STAT-dependent mechanism and induces the expansion of these cells in vivo | Q42139164 | ||
| Molecular mechanisms underlying FOXP3 induction in human T cells | Q42491664 | ||
| Sirolimus versus cyclosporine therapy increases circulating regulatory T cells, but does not protect renal transplant patients given alemtuzumab induction from chronic allograft injury. | Q42636572 | ||
| Physiological sphingosine 1-phosphate requirement for optimal activity of mouse CD4+ regulatory T Cells | Q44844822 | ||
| Rapamycin selectively expands CD4+CD25+FoxP3+ regulatory T cells. | Q45299244 | ||
| Rapamycin promotes expansion of functional CD4+CD25+FOXP3+ regulatory T cells of both healthy subjects and type 1 diabetic patients | Q45864185 | ||
| Rapamycin and interleukin-10 treatment induces T regulatory type 1 cells that mediate antigen-specific transplantation tolerance. | Q45889459 | ||
| Tacrolimus versus cyclosporine induction therapy in pulmonary transplantation in miniature swine | Q46627243 | ||
| Circulating and thymic CD4 CD25 T regulatory cells in myasthenia gravis: effect of immunosuppressive treatment | Q46657338 | ||
| Rapamycin, and not cyclosporin A, preserves the highly suppressive CD27+ subset of human CD4+CD25+ regulatory T cells | Q46739924 | ||
| The sphingosine 1-phosphate receptor agonist FTY720 differentially affects the sequestration of CD4+/CD25+ T-regulatory cells and enhances their functional activity | Q46844009 | ||
| Effect of immunosuppressants on the expansion and function of naturally occurring regulatory T cells | Q46898362 | ||
| Clinical trial: switch to combined mycophenolate mofetil and minimal dose calcineurin inhibitor in stable liver transplant patients--assessment of renal and allograft function, cardiovascular risk factors and immune monitoring | Q46943584 | ||
| Cutting edge: IL-2 is critically required for the in vitro activation of CD4+CD25+ T cell suppressor function | Q47579310 | ||
| Signaling from the IL-2 receptor to the nucleus | Q47992419 | ||
| Differential response of murine CD4+CD25+ and CD4+CD25- T cells to dexamethasone-induced cell death | Q48020712 | ||
| Glucocorticoids upregulate FOXP3 expression and regulatory T cells in asthma. | Q51996007 | ||
| IL-2 receptor beta-dependent STAT5 activation is required for the development of Foxp3+ regulatory T cells. | Q51998742 | ||
| A potential side effect of cyclosporin A: inhibition of CD4(+)CD25(+) regulatory T cells in mice. | Q53583176 | ||
| Increased spontaneous apoptosis of CD4+CD25+ T cells in patients with active rheumatoid arthritis is reduced by infliximab. | Q53659586 | ||
| Altered activation of AKT is required for the suppressive function of human CD4+CD25+ T regulatory cells | Q56901500 | ||
| The immunosuppressive drug FK778 induces regulatory activity in stimulated human CD4+ CD25- T cells | Q56901651 | ||
| Selective survival of naturally occurring human CD4+CD25+Foxp3+ regulatory T cells cultured with rapamycin | Q56901703 | ||
| Regulatory T Cells and T Cell Depletion: Role of Immunosuppressive Drugs | Q57702564 | ||
| CD4 regulatory T cells prevent lethal autoimmunity in IL-2Rbeta-deficient mice. Implications for the nonredundant function of IL-2 | Q74660381 | ||
| Upregulation of Foxp3 expression in mouse and human Treg is IL-2/STAT5 dependent: implications for the NOD STAT5B mutation in diabetes pathogenesis | Q79386860 | ||
| Rapamycin-mediated enrichment of T cells with regulatory activity in stimulated CD4+ T cell cultures is not due to the selective expansion of naturally occurring regulatory T cells but to the induction of regulatory functions in conventional CD4+ T | Q79834605 | ||
| Rapamycin, not cyclosporine, permits thymic generation and peripheral preservation of CD4+ CD25+ FoxP3+ T cells | Q79919091 | ||
| A Foxy tango with NFAT | Q80149222 | ||
| Calcineurin inhibitors, but not rapamycin, reduce percentages of CD4+CD25+FOXP3+ regulatory T cells in renal transplant recipients | Q80154346 | ||
| Cutting edge: T cell requirement for CD28 costimulation is due to negative regulation of TCR signals by PTEN | Q80283949 | ||
| Murine CD4+CD25+ regulatory T cells fail to undergo chromatin remodeling across the proximal promoter region of the IL-2 gene | Q80833054 | ||
| The structure of interleukin-2 complexed with its alpha receptor | Q81810296 | ||
| Overcoming T cell-mediated rejection of bone marrow allografts by T-regulatory cells: synergism with veto cells and rapamycin | Q83853617 | ||
| P433 | issue | 4 | |
| P921 | main subject | interleukins | Q194908 |
| P304 | page(s) | 458-462 | |
| P577 | publication date | 2007-12-18 | |
| P1433 | published in | Cell Cycle | Q1254166 |
| P1476 | title | Interleukin-2 receptor downstream events in regulatory T cells: implications for the choice of immunosuppressive drug therapy | |
| P478 | volume | 7 |
| Q26781342 | A Tale from TGF-β Superfamily for Thymus Ontogeny and Function |
| Q43840575 | Adenosine deaminase potentiates the generation of effector, memory, and regulatory CD4+ T cells. |
| Q30407263 | An old enzyme for current needs: adenosine deaminase and a dendritic cell vaccine for HIV. |
| Q35097239 | An oscillatory switch in mTOR kinase activity sets regulatory T cell responsiveness. |
| Q28752432 | Anti-CD154 mAb and rapamycin induce T regulatory cell mediated tolerance in rat-to-mouse islet transplantation |
| Q41159079 | Different Effects of Tacrolimus on Innate and Adaptive Immune Cells in the Allograft Transplantation |
| Q28475626 | Differential responses of human regulatory T cells (Treg) and effector T cells to rapamycin |
| Q54630277 | Effects of a Janus kinase inhibitor, pyridone 6, on airway responses in a murine model of asthma |
| Q38809772 | Emerging Opportunities and Challenges in Cancer Immunotherapy. |
| Q33697723 | Fine-mapping resolves Eae23 into two QTLs and implicates ZEB1 as a candidate gene regulating experimental neuroinflammation in rat. |
| Q35110765 | High-dose cyclophosphamide for graft-versus-host disease prevention |
| Q35849307 | Histone/protein deacetylases and T-cell immune responses |
| Q41365175 | IL-2 as a therapeutic target for the restoration of Foxp3+ regulatory T cell function in organ-specific autoimmunity: implications in pathophysiology and translation to human disease |
| Q58415034 | Immune Regulation in Hematopoietic Cell Transplantation |
| Q33761278 | Immunoregulatory functions of mTOR inhibition. |
| Q38194133 | Improving engraftment and immune reconstitution in umbilical cord blood transplantation |
| Q28386612 | In vitro exposure to the herbicide atrazine inhibits T cell activation, proliferation, and cytokine production and significantly increases the frequency of Foxp3+ regulatory T cells |
| Q41160178 | JAK inhibition induces silencing of T Helper cytokine secretion and a profound reduction in T regulatory cells |
| Q36195283 | Low-dose IL-2 for In vivo expansion of CD4+ and CD8+ regulatory T cells in nonhuman primates |
| Q37334737 | Mast cells suppress murine GVHD in a mechanism independent of CD4+CD25+ regulatory T cells |
| Q51606652 | Modulation of Immunologic Response by Preventive Everolimus Application in a Rat CPB Model. |
| Q28083146 | Molecular mechanisms underlying β-adrenergic receptor-mediated cross-talk between sympathetic neurons and immune cells |
| Q37861191 | NOTCH and phosphatidylinositide 3-kinase/phosphatase and tensin homolog deleted on chromosome ten/AKT/mammalian target of rapamycin (mTOR) signaling in T-cell development and T-cell acute lymphoblastic leukemia |
| Q38816505 | Novel approaches for preventing acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation |
| Q36130498 | Pathogenesis of acute graft-versus-host disease: from intestinal microbiota alterations to donor T cell activation |
| Q60046969 | Plasma-Derived Inflammatory Proteins Predict Oral Squamous Cell Carcinoma |
| Q38235166 | Potential and limitations of regulatory T-cell therapy in solid organ transplantation. |
| Q46891342 | Rapid and long-lasting decrease of T-regulatory cells in patients with myelofibrosis treated with ruxolitinib. |
| Q42255208 | Ruxolitinib in steroid refractory graft-vs.-host disease: a case report |
| Q35184589 | Sirolimus and mycophenolate mofetil as GVHD prophylaxis in myeloablative, matched-related donor hematopoietic cell transplantation |
| Q39338052 | The emerging role of anti-CD25 directed therapies as both immune modulators and targeted agents in cancer |
| Q38129079 | The role of FOXP3 in regulating immune responses |
| Q35107006 | Transplantation tolerance: Clinical potential of regulatory T cells |
| Q47121682 | Update on Dendritic Cell-Induced Immunological and Clinical Tolerance. |
| Q57805055 | Vitamin C supplementation reconstitutes polyfunctional T cells in streptozotocin-induced diabetic rats |
Search more.